Telos Corporation
NASDAQ:TLSInformation Technology Services
-$0.01 today
- Market cap
- $544.88M
- Beta
- 0.97
- P/E (TTM)
- -12.4
- EPS (TTM)
- -$0.35
Volume 0.84M
Average 0.87M
TLS Other Financing Activities
Financing cash flows not reported separately.
Telos CorporationNASDAQ: TLS
Other Financing Activities · Q1 FY2026 · quarter ended Mar 2026
Other financing activities turns negative
Q1 FY2026 other financing activities was -$6.62M, compared with $0 a year earlier. Trailing-twelve-month other financing activities was -$13.68M.
Context
- Other financing activities amounted to 4.4% of revenue in FY2025, up 4.0 pp from a year earlier.
- Other financing activities increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other financing activities holds near -$6.62M or moves back toward the trailing-twelve-month quarterly average of -$3.42M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Financing Activities history
USD · from the cash flow
- Latest · FY2025
- (7.27M) USD
- Year-over-year change
- -1490.4%
| Period | Period end | Other Financing Activities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (7.27M) | -1490.4% |
| FY2024 | 2024-12-31 | (457K) | +89.7% |
| FY2023 | 2023-12-31 | (4.42M) | -264.3% |
| FY2022 | 2022-12-31 | 2.69M | +109.2% |
| FY2021 | 2021-12-31 | (29.33M) | — |
Other Financing Activities vs competitors
How TLS compares with its peers on the latest reported figures
- Peers report in different currencies, so other financing activities is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +50548.1% is the highest of 9, against a peer median of -41.0%.
- Other financing activities amounts to 7.5% of revenue for TLS, versus a peer median of 1.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $669M USD | +3621.1% | +69.1% | 9.0% | |
| LTM Mar 2026 | $105.36M USD | -33.5% | +125.8% | 13.4% | |
| LTM Mar 2026 | $35.02M USD | -82.3% | +109.8% | 2.0% | |
| LTM Mar 2026 | $13.68M USD | +50548.1% | — | 7.5% | |
| LTM Mar 2026 | $7.36M USD | +60.9% | +63.3% | 2.5% | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥6.89M CNY | — | — | — |
| LTM Mar 2026 | $4.23M USD | +75.4% | +62.6% | 1.7% | |
| LTM Mar 2026 | $1.82M USD | -48.5% | +397.4% | 0.3% | |
| LTM Mar 2026 | $209K USD | -92.3% | -63.5% | 0.1% | |
| LTM Mar 2026 | $10K USD | -99.9% | — | 0.0% | |
| Peer median (excluding TLS) | — | -41.0% | +69.1% | 1.9% | |
Competitors are the stored peer set for TLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (43.13M) | (53.43M) | (34.42M) | (52.52M) | (36.55M) |
| Depreciation & Amortization | 5.62M | 5.89M | 9.43M | 11.87M | 11.45M |
| Deferred Income Tax | 70K | 35K | 55K | 0 | (760K) |
| Stock-Based Compensation | 60.23M | 64.66M | 24.4M | 21.41M | 30.15M |
| Change in Working Capital | (15.57M) | (800K) | 3.33M | (18.55M) | 11.22M |
| Accounts Receivables | (28.94M) | 19.68M | 9.49M | 11.27M | 2.17M |
| Inventory | 2.05M | (1.63M) | 1.46M | (471K) | 634K |
| Accounts Payables | 16.09M | (12.32M) | (8.82M) | (9.42M) | 2.72M |
| Other Working Capital | (4.77M) | (6.52M) | 1.2M | (19.94M) | 5.69M |
| Other Non-Cash Items | 42K | 151K | (1.2M) | 11.86M | 14.67M |
| Operating Cash Flow | 7.26M | 16.51M | 1.59M | (25.94M) | 30.18M |
| Capital Expenditures | (13.17M) | (13.72M) | (15.48M) | (2.25M) | (739K) |
| Acquisitions (Net) | (5.93M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (3M) | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (9.97M) | (12.71M) | (14.55M) | (11.51M) | (8.18M) |
| Investing Cash Flow | (19.09M) | (13.72M) | (15.48M) | (16.76M) | (8.92M) |
| Debt Repayment | (1.34M) | (1.46M) | (1.59M) | (1.73M) | (1.88M) |
| Common Stock Issued | 64.27M | 0 | 0 | 203K | 108K |
| Common Stock Repurchased | (1.25M) | (11.15M) | (139K) | 0 | (13.63M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (29.33M) | 2.69M | (4.42M) | (457K) | (7.27M) |
| Financing Cash Flow | 32.35M | (9.92M) | (6.15M) | (1.98M) | (22.66M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 20.52M | (7.12M) | (20.04M) | (44.68M) | (1.4M) |
| Free Cash Flow | (5.91M) | 2.79M | (13.89M) | (28.19M) | 29.44M |
Telos Corporation
NASDAQ:TLS
Intrinsic Alpha fair value
Locked
Current Price
$7.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.